Neeraj Kumar Agrawal

Prof. Neeraj Kumar Agrawal

Institute of Medical Sciences, Vārānasi, Uttar Pradesh, International
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Diabetes
Verified
Journal Article
Open access
NANeeraj Kumar Agrawal
Neeraj Kumar Agrawal
SKSaket Kant
Saket Kant
Inflammation has been recognised to both decrease beta cell insulin secretion and increase insulin resistance. Circulating cytokines can affect beta cell function directly leading to secretory dysfunction and increased apoptosis. These cytokines can also indirectly affect beta cell function by increasing adipocyte inflammation.The resulting glucotoxicity and lipotoxicity further enhance the inflammatory process resulting in a vicious cycle. Weight reduction and drugs such as metformin have been shown to decrease the levels of C-Reactive Protein by 31% and 13%, respectively. Pioglitazone, insulin and statins have anti-inflammatory effects. Interleukin 1 and tumor necrosis factor-α antagonists are in trials and NSAIDs such as salsalate have shown an improvement in insulin sensitivity. Inhibition of 12-lipo-oxygenase, histone de-acetylases, and activation of sirtuin-1 are upcoming molecular targets to reduce inflammation. These therapies have also been shown to decrease the conversion of pre-diabetes state to diabetes. Drugs like glicazide, troglitazone, N-acetylcysteine and selective COX-2 inhibitors have shown benefit in diabetic neuropathy by decreasing inflammatory markers. Retinopathy drugs are used to target vascular endothelial growth factor, angiopoietin-2, various proteinases and chemokines. Drugs targeting the proteinases and various chemokines are pentoxifylline, inhibitors of nuclear factor-kappa B and mammalian target of rapamycin and are in clinical trials for diabetic nephropathy. Commonly used drugs such as insulin, metformin, peroxisome proliferator-activated receptors, glucagon like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors also decrease inflammation. Anti-inflammatory therapies represent a potential approach for the therapy of diabetes and its complications.

1 September 2008 in Postgraduate Medical Journal
Verified
Journal Article
Closed access
PDF file
NANeeraj Kumar Agrawal
Neeraj Kumar Agrawal
RGR Goyal
R Goyal
ARA Rastogi
A Rastogi
DND Naik
D Naik
SSS K Singh
S K Singh
Thyroid hormone resistance (THR) is a rare syndrome of reduced end organ sensitivity. Patients with THR have elevated serum free thyroxine (FT4), free triiodothyronine (FT3), but normal or slightly elevated serum thyrotropin values. The characteristic clinical feature is goitre without symptoms and metabolic consequences of thyroid hormone excess. THR can be classified on the basis of tissue resistance into pituitary, peripheral or generalised (both pituitary and peripheral) types. Mutations in the TRβ gene, cell membrane transporter and genes controlling intracellular metabolism of thyroid hormone have been implicated. THR is differentiated from thyroid stimulating hormone (TSH) secreting pituitary adenoma by history of THR in the family. No specific treatment is often required for THR; patients with features of hypo- or hyperthyroidism are appropriately treated with levo-triiodothyronine (L-T3), levo-thyroxine (L-T4), dextro-thyroxine(D-T4) or 3,3,5 triiodo-thyroacetic acid (TRIAC). The diagnosis helps in appropriate genetic counselling of the family.

1 February 2013 in Archives of Osteoporosis
Verified
Journal Article
Closed access
PDF file
NANeeraj Kumar Agrawal
Neeraj Kumar Agrawal
BSBalram Sharma
Balram Sharma

1 August 2007 in Pharmacological Research
Verified
Journal Article
Closed access
NANeeraj Kumar Agrawal
Neeraj Kumar Agrawal
RMR Maiti
R Maiti
DDD Dash
D Dash
BPB Pandey
B Pandey

1 January 2015 in Environmental Toxicology and Pharmacology
Verified
Journal Article
Closed access
SCShikha Chouhan
Shikha Chouhan
SYSatyndra Kumar Yadav
Satyndra Kumar Yadav
JPJay Prakash
Jay Prakash
SWSusan Westfall
Susan Westfall
AGAmrita Ghosh
Amrita Ghosh
SSSurya Pratap Singh
Surya Pratap Singh

1 August 2007 in Vascular Pharmacology
Verified
Journal Article
Closed access
RMRituparna Maiti
Rituparna Maiti
NANeeraj Kumar Agrawal
Neeraj Kumar Agrawal
DDD. Dash
D. Dash
BPB.L. Pandey
B.L. Pandey